| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
Dimethandrolone Undecanoate is an androgen receptor modulator (SARM). It inhibits production of gonadotropins, suppresses testosterone production, and thus inhibits sperm production. It exhibits both androgenic and progestational activities.
|
|---|---|
| ln Vitro |
In vitro, dimethandrolone undecanoate acts as an androgen receptor modulator. It inhibits gonadotropin production. Its dual mechanism of action has been characterized in various cell-based assays.
|
| ln Vivo |
In vivo, dimethandrolone undecanoate is being investigated for its potential use in hormone replacement therapy (HRT) and male contraception. It suppresses testosterone production and inhibits sperm production. It is under investigation in clinical trial NCT03455075.
|
| Enzyme Assay |
In vitro receptor binding assays for dimethandrolone undecanoate typically use membrane preparations from cells expressing androgen and progesterone receptors. Radiolabeled ligands are displaced by increasing concentrations of the compound to determine binding affinity. Functional assays measure receptor-mediated transcriptional activity.
|
| Cell Assay |
Cell-based assays for dimethandrolone undecanoate involve treating cells expressing androgen or progesterone receptors with the compound and measuring receptor-mediated transcriptional activity. Cells transfected with responsive reporter genes are treated with varying concentrations of the compound. Reporter gene activity is measured. EC50 values are calculated.
|
| Animal Protocol |
In vivo animal studies for dimethandrolone undecanoate typically involve oral administration to animal models. Effects on gonadotropin levels, testosterone production, and spermatogenesis are assessed. The compound's contraceptive efficacy and safety are evaluated.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of dimethandrolone undecanoate are characteristic of orally active androgens. The undecanoate ester prolongs the duration of action. The compound is absorbed following oral administration and distributed to tissues. Metabolism occurs in the liver. Excretion occurs through renal pathways.
|
| Toxicity/Toxicokinetics |
The toxicological profile of dimethandrolone undecanoate has been evaluated in preclinical and clinical studies. The compound is generally well-tolerated. Common side effects include androgenic and progestational effects. Long-term safety data are being accumulated.
|
| References | |
| Additional Infomation |
Dimethandrolone undecanoate is being studied in the clinical trial NCT03455075 (investigating the effect of DMAU alone or in combination with LNG on the inhibition of spermatogenesis in normal men compared with the effect of placebo alone).
Dimethandrolone Undecanoate (DMAU) is a novel, orally available androgen with progestational activity. It is an investigational oral male contraceptive agent. It is under investigation in clinical trials. It is not currently approved for clinical use. |
| Molecular Formula |
C31H50O3
|
|---|---|
| Molecular Weight |
470.727
|
| Exact Mass |
470.376
|
| CAS # |
366472-45-9
|
| PubChem CID |
67333747
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
8.5
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
34
|
| Complexity |
754
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
CCCCCCCCCCC(=O)O[C@H]1CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2[C@@H](CC4=CC(=O)CC[C@H]34)C)C)C
|
| InChi Key |
FVICENFBEMJOCE-RTFNQGFNSA-N
|
| InChi Code |
InChI=1S/C31H50O3/c1-5-6-7-8-9-10-11-12-13-28(33)34-27-17-16-26-30-21(2)18-23-19-24(32)14-15-25(23)29(30)22(3)20-31(26,27)4/h19,21-22,25-27,29-30H,5-18,20H2,1-4H3/t21-,22+,25+,26+,27+,29-,30+,31+/m1/s1
|
| Chemical Name |
[(7R,8R,9S,10R,11S,13S,14S,17S)-7,11,13-trimethyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl] undecanoate
|
| Synonyms |
DMAU; Dimethandrolone Undecanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1244 mL | 10.6218 mL | 21.2436 mL | |
| 5 mM | 0.4249 mL | 2.1244 mL | 4.2487 mL | |
| 10 mM | 0.2124 mL | 1.0622 mL | 2.1244 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
